ABVC BioPharma, Inc. (ABVC)

Market Cap	26.44M -63.1%
Revenue (ttm)	n/a
Net Income	-7.11M
EPS	-0.29
Shares Out	25.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55,896
Open	1.000
Previous Close	0.979
Day's Range	0.960 - 1.030
52-Week Range	0.707 - 3.070
Beta	0.51
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 2, 2026

About ABVC

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 19
• Stock Exchange: Nasdaq
• Ticker Symbol: ABVC
• Website: https://www.abvcpharma.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 14, 2026

Data Sources Report a data error